InsidersTradesSigma
Explore the full directors' dealings record of REPROS THERAPEUTICS INC., a listed issuer based in United States. Shares are listed on US US, under the supervision of SEC (Form 4). Market capitalisation: €31.8bn. The latest transaction was filed on 28 January 2016 (Acquisition). Among the most active insiders: Wernicke J. F.. The full history is accessible without an account.
Analysts rate REPROS THERAPEUTICS INC. Strong Buy (bullish), based on 8 analysts. Average price target: US$59.25.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
6 of 6 declarations
REPROS THERAPEUTICS INC. is a biopharmaceutical company focused on developing treatments for hormonal and reproductive disorders. It is listed on NASDAQ under the ticker RPRX.